Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381089 | 1.00 | CTSC (0.39) | CTSCACACBSLC15A2 | |
| SCHEMBL15271276 | 1.00 | CTSC (0.39) | CTSCACACBSLC15A2 | |
| SCHEMBL4409880 | 0.89 | CTSC (0.32) | CTSC | |
| SCHEMBL4589893 | 0.84 | ACACB (0.34) | ACACB | |
| SCHEMBL7288407 | 0.83 | ACACB (0.32) | ACACB | |
| SCHEMBL2184592 | 0.83 | ACACB (0.32) | ACACB | |
| SCHEMBL9012459 | 0.82 | CTSC (0.37) | CTSC | |
| SCHEMBL9012442 | 0.82 | CTSC (0.37) | CTSC | |
| SCHEMBL9012647 | 0.82 | CTSC (0.37) | CTSC | |
| SCHEMBL9012638 | 0.82 | CTSC (0.37) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994018230-A1 | INHIBITION OF HIV REPLICATION BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1994-08-18 | — | — | WO | claimed |
| US-4665054-A | GLYCYL-HISTIDYL-LYSINE COPPER CHELATE | BIOHEAL, INC. (US) | 1987-05-12 | — | — | US | claimed |
| EP-2822610-A1 | ENZYME-ACTIVATED COLLAGEN AND TISSUE MATRICES | Lifecell Corporation (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013134009-A1 | ENZYME-ACTIVATED COLLAGEN AND TISSUE MATRICES | LIFECELL CORPORATION (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| US-7169605-B2 | Methods of controlling proliferation and differentiation of stem and progenitor cells | GAMIDA CELL LTD. (IL) | 2007-01-30 | — | — | US | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1633385-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ROSACEA | PROCYTE CORPORATION (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1613302-A2 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050214262-A1 | Methods of controlling proliferation and differentiation of stem and progenitor cells | GAMIDA CELL INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2004004671-A1 | COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND SOFT TISSUE FILLERS | PROCYTE CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003030860-A1 | SKIN CARE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND RETINOL, RETINOL DERIVATIVES, OR A MIXTURE THEREOF | PROCYTE CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-1994018230-A1 | INHIBITION OF HIV REPLICATION BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0522004-A1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5177061-A | Method for stimulating hair growth using GHL-Cu complexes | PROCYTE CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1991014437-A2 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| EP-0420914-A1 | COSMETIC AND SKIN TREATMENT COMPOSITIONS. | PROCYTE CORP (US) | 1991-04-10 | — | — | EP | disclosed |
| WO-1989012441-A1 | COSMETIC AND SKIN TREATMENT COMPOSITIONS | PROCYTE CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0288278-A2 | Chemical derivatives of GHL-CU | PROCYTE CORPORATION (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | CTSC 192/4885ACACB 3069/4885SLC15A2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.